DCM
VRTX icon

Davis Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Davis Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.97K Buy
8
+5
+167% +$2.22K ﹤0.01% 333
2026
Q1 		$1.34K Buy
3
+1
+50% +$466 ﹤0.01% 315
2025
Q4 		$907 Hold
2
– – ﹤0.01% 342
2025
Q3 		$783 Buy
+2
New +$836 ﹤0.01% 358

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Davis Capital Management's VRTX Position: Q2 2026 in Review

Davis Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 167% in Q2 2026, buying an estimated $2.22K and bringing the position to 8 shares worth $3.97K. The position accounts for ﹤0.01% of the portfolio, ranked #333.

Davis Capital Management first reported a position in VRTX in Q3 2025 and has held it in 4 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Davis Capital Management held 8 shares of Vertex Pharmaceuticals worth $3.97K as of Q2 2026.
  • Davis Capital Management bought 5 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.22K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #333 holding.
  • Davis Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.